Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


03.12.2018

1 BMC Cancer
2 BMC Urol
2 Clin Genitourin Cancer
3 Eur Urol
1 Eur Urol Focus
1 Genes Genomics
1 Int J Mol Sci
1 J Cancer Res Ther
1 J Cell Biochem
1 J Cell Mol Med
2 J Cell Physiol
1 J Exp Clin Cancer Res
3 JAMA Surg
1 Med Oncol
1 Neoplasia
1 Oncol Rep
1 PLoS One
1 Turk J Urol
1 Urol J
2 Urol Oncol
2 Urology
1 Vet Comp Oncol
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. MAEDA S, Tomiyasu H, Tsuboi M, Inoue A, et al
    Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.
    BMC Cancer. 2018;18:472.
    PubMed     Text format     Abstract available


    BMC Urol

  2. KIM YS, Kim K, Kwon GY, Lee SJ, et al
    Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
    BMC Urol. 2018;18:68.
    PubMed     Text format     Abstract available

  3. QUIRK H, Rosario DJ, Bourke L
    Supportive interventions to improve physiological and psychological health outcomes among patients undergoing cystectomy: a systematic review.
    BMC Urol. 2018;18:71.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  4. ROYCE TJ, Feldman AS, Mossanen M, Yang JC, et al
    Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2018 Oct 4. pii: S1558-7673(18)30586.
    PubMed     Text format     Abstract available

  5. TAYLOR BL, Matrai CE, Smith AL, Ayangbesan A, et al
    Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?
    Clin Genitourin Cancer. 2018 Oct 29. pii: S1558-7673(18)30567.
    PubMed     Text format     Abstract available


    Eur Urol

  6. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed     Text format    

  7. HENRIQUE R, Nunes SP, Jeronimo C
    MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges.
    Eur Urol. 2018 Nov 20. pii: S0302-2838(18)30871.
    PubMed     Text format    

  8. PANEBIANCO V, Barentsz J, Narumi Y, Catto JWF, et al
    Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imagi
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30720.
    PubMed     Text format    


    Eur Urol Focus

  9. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Eur Urol Focus. 2018 Nov 20. pii: S2405-4569(18)30337.
    PubMed     Text format     Abstract available


    Genes Genomics

  10. KIM TN, Kim WT, Jeong MS, Mun MH, et al
    Short rare minisatellite variant of BORIS-MS2 is related to bladder cancer susceptibility.
    Genes Genomics. 2018 Nov 29. pii: 10.1007/s13258-018-0771.
    PubMed     Text format     Abstract available


    Int J Mol Sci

  11. YAMASAKI K, Mukai S, Nagai T, Nakahara K, et al
    Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available


    J Cancer Res Ther

  12. YU C, Hequn C, Jinbo C, Feng Z, et al
    Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis.
    J Cancer Res Ther. 2018;14:1260-1265.
    PubMed     Text format     Abstract available


    J Cell Biochem

  13. WANG Y, Shi F, Xia Y, Zhao H, et al
    LncRNA OIP5-AS1 predicts poor prognosis and regulates cell proliferation and apoptosis in bladder cancer.
    J Cell Biochem. 2018 Nov 28. doi: 10.1002/jcb.28024.
    PubMed     Text format     Abstract available


    J Cell Mol Med

  14. ZHANG S, Du L, Wang L, Jiang X, et al
    Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer.
    J Cell Mol Med. 2018 Nov 23. doi: 10.1111/jcmm.14042.
    PubMed     Text format     Abstract available


    J Cell Physiol

  15. AGHAALIKHANI N, Rashtchizadeh N, Shadpour P, Allameh A, et al
    Cancer stem cells as a therapeutic target in bladder cancer.
    J Cell Physiol. 2018 Nov 23. doi: 10.1002/jcp.26916.
    PubMed     Text format     Abstract available

  16. XIE H, Huang H, Huang W, Xie Z, et al
    LncRNA miR143HG suppresses bladder cancer development through inactivating Wnt/beta-catenin pathway by modulating miR-1275/AXIN2 axis.
    J Cell Physiol. 2018 Nov 23. doi: 10.1002/jcp.27764.
    PubMed     Text format     Abstract available


    J Exp Clin Cancer Res

  17. QIANG Z, Zhou ZY, Peng T, Jiang PZ, et al
    Inhibition of TPL2 by interferon-alpha suppresses bladder cancer through activation of PDE4D.
    J Exp Clin Cancer Res. 2018;37:288.
    PubMed     Text format     Abstract available


    JAMA Surg

  18. EFSTATHIOU JA, Choudhury A, Kiltie AE
    Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    JAMA Surg. 2018 Nov 21. pii: 2714602. doi: 10.1001/jamasurg.2018.4370.
    PubMed     Text format    

  19. WILLIAMS SB, Kamat AM, Mehta HB
    Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply.
    JAMA Surg. 2018 Nov 21. pii: 2714604. doi: 10.1001/jamasurg.2018.4372.
    PubMed     Text format    

  20. MOLITORIS JK, Simone CB 2nd
    Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    JAMA Surg. 2018 Nov 21. pii: 2714603. doi: 10.1001/jamasurg.2018.4371.
    PubMed     Text format    


    Med Oncol

  21. OKITA K, Hatakeyama S, Fujita N, Konishi S, et al
    Postoperative weight loss followed by radical cystectomy predicts poor prognosis in patients with muscle-invasive bladder cancer.
    Med Oncol. 2018;36:7.
    PubMed     Text format     Abstract available


    Neoplasia

  22. LI WT, Zheng H, Nguyen V, Wang-Rodriguez J, et al
    Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker.
    Neoplasia. 2018;20:364-373.
    PubMed     Text format     Abstract available


    Oncol Rep

  23. ZHANG J, Mao S, Wang L, Zhang W, et al
    MicroRNA154 functions as a tumor suppressor in bladder cancer by directly targeting ATG7.
    Oncol Rep. 2018 Nov 21. doi: 10.3892/or.2018.6879.
    PubMed     Text format     Abstract available


    PLoS One

  24. YUK HD, Jeong CW, Kwak C, Kim HH, et al
    Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    PLoS One. 2018;13:e0208267.
    PubMed     Text format     Abstract available


    Turk J Urol

  25. BIALEK L, Poletajew S, Magusiak PM, Ostrach M, et al
    Bimanual palpation for staging of bladder cancer-clinical use and its predictors.
    Turk J Urol. 2018 Nov 21. pii: tud.2018.27243. doi: 10.5152/tud.2018.27243.
    PubMed     Text format     Abstract available


    Urol J

  26. KRAJEWSKI W, Zdrojowy R, Grzegolka J, Krajewski P, et al
    Does Mantoux Test Result Predicts BCG Immunotherapy Efficiency and Severe ToXxicity in Non-Muscle Invasive Bladder Cancer.
    Urol J. 2018 Nov 21. pii: 4542/1319.
    PubMed     Text format     Abstract available


    Urol Oncol

  27. BAZARGANI ST, Clifford TG, Djaladat H, Schuckman AK, et al
    Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
    Urol Oncol. 2018 Nov 20. pii: S1078-1439(18)30349.
    PubMed     Text format     Abstract available

  28. LIN-BRANDE M, Nazemi A, Pearce SM, Thompson ER, et al
    Assessing trends in urinary diversion after radical cystectomy for bladder cancer in the United States.
    Urol Oncol. 2018 Nov 25. pii: S1078-1439(18)30449.
    PubMed     Text format     Abstract available


    Urology

  29. KWAN ML, Leo MC, Danforth KN, Weinmann S, et al
    Factors that Influence Selection of Urinary Diversion among Bladder Cancer Patients in Three Community-Based Integrated Health Care Systems.
    Urology. 2018 Nov 21. pii: S0090-4295(18)31217.
    PubMed     Text format     Abstract available

  30. TONG C, Daskalakis N, Edwards DC, Cahn DB, et al
    Malignant Infiltration of the Penis From Urothelial Carcinoma of the Bladder.
    Urology. 2017 Mar 31. pii: S0090-4295(17)30302.
    PubMed     Text format    


    Vet Comp Oncol

  31. SAKAI K, Maeda S, Saeki K, Nakagawa T, et al
    Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.
    Vet Comp Oncol. 2018;16:642-649.
    PubMed     Text format     Abstract available


    World J Urol

  32. FAIENA I, Rosser CJ, Chamie K, Furuya H, et al
    Diagnostic biomarkers in non-muscle invasive bladder cancer.
    World J Urol. 2018 Nov 22. pii: 10.1007/s00345-018-2567.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: